COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
capmatinib- Repurposed
Announced capmatinib showed robust antiviral effects in experimental Covid-19 models.
Ryerson University
The Vector Institute
Adagio Therapeutics, Inc.
Started Phase 1/2/3 study in high-risk people with mild to moderate COVID-19.
Phase 2/3 study to start in the second half of 2021.
Eli Lilly And Co.
LY-CoV555, also known as Bamlanivimab
Phase 2 trial of LY3819253, alone or in combination with either LY3832479 or VIR-7831 in low-risk adults with COVID-19 (BLAZE-4) began in Jan.2020
-- Positive results from BLAZE-4 trial reported on Mar.29,2021
Vir Biotechnology and GSK
DYAI-100 advancing towards first-in-human Phase 1 clinical trial
ImmunoPrecise Antibodies Ltd.
Out of 27 antibodies screened, 23-H7 has been identified as the one with a potential to fight SARS-CoV-2 variants of concern
Laurent Pharmaceuticals
The independent Data Safety Monitoring Board (DSMB) for the phase 2 study of LAU-7b, dubbed Resolution, recommended to continue the study without modification.
Top line results are expected in the second half of 2021.
Aimmune Therapeutics Inc.
Ampligen as a potential prophylaxis or treatment for COVID-19
-- Positive safety data in 1st cohort of phase I study of Intranasal Ampligen as potential prophylaxis or treatment for COVID-19 reported on Apr.7, 2021

--Phase 1 study of Ampligen as a potential intranasal therapy in healthy subjects
Commencement of Phase 2 studies
Innovation Pharmaceuticals Inc.
Innovation Pharma said an independent Data Monitoring Committee approved increased dosing frequency in phase II study of Brilacidinin hospitalized Covid-19 patients.

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
The Inter-American Development Bank and Citi Innovation Labs have successfully completed a proof-of-concept to make cross-border payments from the U.S. to countries in Latin America and the Caribbean, using blockchain and tokenized money. The platform provided full traceability of the transactions, exchange rates, and fees on blockchain. Australian competition regulator said the country's Federal Court found that Google and its Australian arm misled users about the collection and use of personal location data. The data was collected through Android mobile devices between January 2017 and December 2018. This is said to be the world-first enforcement action brought by the Australian Competition and Consumer Commission or ACCC. Morgan Stanley (MS) reported a first-quarter profit that more than doubled from last year, reflecting strong performance across all of its business segment. Net revenues for the quarter grew 61 percent from the previous year. Quarterly adjusted earnings per share beat analysts' estimates.